Status:
COMPLETED
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
Lead Sponsor:
GlaxoSmithKline
Conditions:
Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This Phase II study is designed to evaluate the anti-tumor activity of three dose groups of SB-485232 (0.01, 0.1, and 1.0 mg/kg/day) administered intravenously as a single agent in subjects with previ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients must have melanoma that has spread beyond the original location and has not yet been treated.
- Tissue from the spreading melanoma should have been tested to confirm it is melanoma.
- Exclusion criteria:
- Patients having hepatitis or HIV infection.
- Taking corticosteroids.
- Patients with the primary site being occular melanoma or patients with melanoma of the brain.
Exclusion
Key Trial Info
Start Date :
November 15 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 19 2006
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00107718
Start Date
November 15 2004
End Date
May 19 2006
Last Update
July 27 2017
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Los Angeles, California, United States, 90089
2
GSK Investigational Site
San Francisco, California, United States, 94115
3
GSK Investigational Site
Santa Monica, California, United States, 90404-2104
4
GSK Investigational Site
New Haven, Connecticut, United States, 06520